Hematology & Hematological Oncology

Building on Chimeric Antigen Receptor (CAR) therapy for cancer, we have created and expanded human “natural” regulatory T cells (Tregs), as well as cytotoxic T cells that are rendered specific by expression of either T-cell receptor (TCR), single chain Fv (scFv) V regions or a novel CAR derivative, called B-cell antibody receptors (BAR). These specific Tregs demonstrate potent suppression of T-cell and B-cell responses in two disease models, MS and hemophilia, in vitro and in vivo. These cells are stable, specific and potent. Engineered BAR cytotoxic cells have also been generated that can directly target and kill specific B cells. Our results are a platform to generate T cells that can be used to block adverse immune responses. Translation into large animals and clinical trials are planned.